Natco Pharma applies to CDSCO for Phase-III clinical trial of Molnupiravir Capsules for Covid-19 treatment

26 Apr 2021 Evaluate

Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients. Pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

840.40 -4.80 (-0.57%)
20-Jan-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1641.45
Dr. Reddys Lab 1191.65
Cipla 1381.10
Zydus Lifesciences 879.35
Lupin 2169.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×